These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 1147)
1. L-[alphaS, 5S]-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (NSC-163501): a new amino acid antibiotic with the properties of an antagonist of L-glutamine. Jayaram HN; Cooney DA; Ryan JA; Neil G; Dion RL; Bono VH Cancer Chemother Rep; 1975; 59(3):481-91. PubMed ID: 1147 [TBL] [Abstract][Full Text] [Related]
2. Enhanced effect of an L-glutamine antagonist, L-(alphaS,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid, by Acinetobacter L-glutaminase-L-asparaginase. Holcenberg JS Cancer Treat Rep; 1979 Jun; 63(6):1109-14. PubMed ID: 466650 [TBL] [Abstract][Full Text] [Related]
3. Mechanism of resistance of a variant of P388 leukemia to L-(alpha S,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin). Jayaram HN; Ardalan B; Deas M; Johnson RK Cancer Res; 1985 Jan; 45(1):207-12. PubMed ID: 2578092 [TBL] [Abstract][Full Text] [Related]
4. Biochemical and pharmacological effects of the fermentation-derived antitumor agent, (alphaS,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125). Neil GL; Berger AE; McPartland RP; Grindey GB; Bloch A Cancer Res; 1979 Mar; 39(3):852-6. PubMed ID: 427775 [No Abstract] [Full Text] [Related]
5. The inhibition of gamma-glutamyl transpeptidase from human pancreatic carcinoma cells by (alpha S,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125; NSC-163501). Allen L; Meck R; Yunis A Res Commun Chem Pathol Pharmacol; 1980 Jan; 27(1):175-82. PubMed ID: 6102405 [TBL] [Abstract][Full Text] [Related]
6. Studies of the biochemical pharmacology of the fermentation-derived antitumor agent, (alpha S, 5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125). Neil GL; Berger AE; Bhuyan BK; Blowers CL; Kuentzel SL Adv Enzyme Regul; 1978; 17():375-98. PubMed ID: 757314 [No Abstract] [Full Text] [Related]
7. Mechanism of inactivation of glutamine amidotransferases by the antitumor drug L-(alpha S, 5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125). Tso JY; Bower SG; Zalkin H J Biol Chem; 1980 Jul; 255(14):6734-8. PubMed ID: 6993476 [TBL] [Abstract][Full Text] [Related]
8. Acivicin. An antitumor antibiotic. Poster DS; Bruno S; Penta J; Neil GL; McGovren JP Cancer Clin Trials; 1981; 4(3):327-30. PubMed ID: 7026076 [TBL] [Abstract][Full Text] [Related]
9. A new antitumor agent, (alphas, 4s, 5r)-alpha-amino-3-chloro-4-hydroxy-4,5-dihydro-5-isoxazoleacetic acid (NSC-176324): preliminary evaluation against L 1210 mouse leukemia in vivo. Martin DG; Hanka LJ; Neil GL Cancer Chemother Rep; 1974; 58(6):935-7. PubMed ID: 4217217 [No Abstract] [Full Text] [Related]
10. The inhibition of gamma-glutamyl transpeptidase and glutathione metabolism of isolated rat kidney cells by L-(alpha S, 5S)-alpha-amino-3-chloro-4, 5-dihydro-5-isoxazoleacetic acid (AT-125; NSC-163501). Reed DJ; Ellis WW; Meck RA Biochem Biophys Res Commun; 1980 Jun; 94(4):1273-7. PubMed ID: 6104962 [No Abstract] [Full Text] [Related]
11. Enhancement of antitumor activity of glutamine antagonists 6-diazo-5-oxo-L-norleucine and acivicin in cell culture by glutaminase-asparaginase. Rosenfeld H; Roberts J Cancer Res; 1981 Apr; 41(4):1324-8. PubMed ID: 7214322 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of cell cycle progression of human pancreatic carcinoma cells in vitro by L-(alpha S, 5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid, Acivicin (NSC 163501). Meck RA; Clubb KJ; Allen LM; Yunis AA Cancer Res; 1981 Nov; 41(11 Pt 1):4547-53. PubMed ID: 7306976 [TBL] [Abstract][Full Text] [Related]
13. In vivo inactivation by acivicin of carbamoyl-phosphate synthetase II in rat hepatoma. Aoki T; Sebolt J; Weber G Biochem Pharmacol; 1982 Mar; 31(6):927-32. PubMed ID: 7082374 [TBL] [Abstract][Full Text] [Related]
14. Monocytoid differentiation of freshly isolated human myeloid leukemia cells and HL-60 cells induced by the glutamine antagonist acivicin. Nichols KE; Chitneni SR; Moore JO; Weinberg JB Blood; 1989 Oct; 74(5):1728-37. PubMed ID: 2790198 [TBL] [Abstract][Full Text] [Related]
15. Cytotoxic mechanisms of glutamine antagonists in mouse L1210 leukemia. Lyons SD; Sant ME; Christopherson RI J Biol Chem; 1990 Jul; 265(19):11377-81. PubMed ID: 2358467 [TBL] [Abstract][Full Text] [Related]
16. A new antitumor antimetabolite, (alphaS,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (NSC-163501): antimicrobial reversal studies and preliminary evaluation against L1210 mouse leukemia in vivo. Hanka LJ; Martin DG; Neil GL Cancer Chemother Rep; 1973 Apr; 57(2):141-8. PubMed ID: 4200486 [No Abstract] [Full Text] [Related]
17. Biochemical pharmacology of acivicin in rat hepatoma cells. Lui MS; Kizaki H; Weber G Biochem Pharmacol; 1982 Nov; 31(21):3469-73. PubMed ID: 7150366 [TBL] [Abstract][Full Text] [Related]
18. In vivo inactivation of formylglycinamidine ribonucleotide synthetase in rat hepatoma. Elliott WL; Weber G Biochem Pharmacol; 1985 Jan; 34(2):243-8. PubMed ID: 3966925 [TBL] [Abstract][Full Text] [Related]
19. Inactivation by acivicin of carbamoyl-phosphate synthetase II of human colon carcinoma. Sebolt JS; Aoki T; Eble JN; Glover JL; Weber G Biochem Pharmacol; 1985 Jan; 34(1):97-100. PubMed ID: 3966920 [TBL] [Abstract][Full Text] [Related]
20. Aspects of glutamine metabolism in human tumour cells. Colquhoun A; Newsholme EA Biochem Mol Biol Int; 1997 Mar; 41(3):583-96. PubMed ID: 9090467 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]